Telithromycin (HMR3647)

Phase 3Completed

1 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Otitis Media

Conditions

Otitis Media

Trial Timeline

Feb 1, 2004 → Oct 1, 2004

NCT ID

NCT00638534

About Telithromycin (HMR3647)

Telithromycin (HMR3647) is a phase 3 stage product being developed by Sanofi for Otitis Media. The current trial status is completed. This product is registered under clinical trial identifier NCT00638534. Target conditions include Otitis Media.

What happened to similar drugs?

2 of 11 similar drugs in Otitis Media were approved

Approved (2) Terminated (2) Active (7)

🔄ofloxacin otic solution 0.3%Daiichi SankyoPhase 3

🔄levofloxacinJohnson & JohnsonPhase 3

🔄levofloxacin; amoxicillin/clavulanateJohnson & JohnsonPhase 3

🔄V114MerckPhase 3

✅Montelukast + PlaceboMerckApproved

🔄7-valent pneumococcal-CRM197 conjugate vaccine + 7-valent pneumococcal-OMPC conjugate vaccineMerckPhase 3

🔄ZmaxPfizerPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (4)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00174811	Phase 3	Terminated	Jun 1, 2005	Jun 1, 2006	Otitis Media
NCT00408135	Phase 3	Completed	Aug 1, 2004	May 1, 2005	Infections
NCT00638859	Phase 3	Completed	Mar 1, 2004	Oct 1, 2004	Pneumonia
NCT00638534	Phase 3	Completed	Feb 1, 2004	Oct 1, 2004	Otitis Media

Competing Products

15 competing products in Otitis Media

See all competitors

Product	Company	Stage	Hype Score
piperacillin 4% + tazobactam 0.5% + dexamethasone 0.1% + piperacillin 8% + tazobactam 1.0% + dexamethasone 0.1% + piperacillin 2% + tazobactam 0.25% + piperacillin 4% + tazobactam 0.5% + piperacillin 8% + tazobactam 1.0%	Yuhan	Phase 1/2	24
ofloxacin otic solution 0.3%	Daiichi Sankyo	Phase 3	40
levofloxacin	Johnson & Johnson	Phase 3	40
levofloxacin; amoxicillin/clavulanate	Johnson & Johnson	Phase 3	40
V114	Merck	Phase 3	40
Montelukast + Placebo	Merck	Approved	43
7-valent pneumococcal-CRM197 conjugate vaccine + 7-valent pneumococcal-OMPC conjugate vaccine	Merck	Phase 3	40
Prevenar	Pfizer	Pre-clinical	26
Zmax	Pfizer	Phase 3	40
Observational	Pfizer	Pre-clinical	26
Saline + Fentanyl + Dexmedetomidine + Dexmedetomidine	Pfizer	Approved	43
amoxicillin/clavulanate postassium (Augmentin ES-600) + azithromycin SR	Pfizer	Phase 3	40
60 mg/kg azithromycin ER + 30 mg/kg azithromycin IR	Pfizer	Phase 2	35
telithromycin (HMR3647)	Sanofi	Phase 3	32
Telithromycin + Azithromycin	Sanofi	Phase 3	32